MOSCA, MARTA
 Distribuzione geografica
Continente #
NA - Nord America 20.913
AS - Asia 10.911
EU - Europa 6.740
SA - Sud America 2.384
AF - Africa 541
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 8
Totale 41.527
Nazione #
US - Stati Uniti d'America 20.343
SG - Singapore 3.576
CN - Cina 2.969
HK - Hong Kong 2.217
IT - Italia 2.016
BR - Brasile 1.991
SE - Svezia 1.132
VN - Vietnam 816
BG - Bulgaria 757
DE - Germania 719
GB - Regno Unito 475
CA - Canada 415
TR - Turchia 377
RU - Federazione Russa 366
FI - Finlandia 343
IN - India 240
CI - Costa d'Avorio 193
FR - Francia 170
AR - Argentina 145
UA - Ucraina 145
KR - Corea 126
AT - Austria 109
JP - Giappone 93
NL - Olanda 93
SN - Senegal 89
MX - Messico 85
ID - Indonesia 84
BD - Bangladesh 79
NG - Nigeria 68
EC - Ecuador 65
PL - Polonia 64
ES - Italia 63
BE - Belgio 60
IQ - Iraq 54
ZA - Sudafrica 52
CO - Colombia 44
MA - Marocco 44
CH - Svizzera 42
VE - Venezuela 38
PK - Pakistan 33
SA - Arabia Saudita 31
PY - Paraguay 29
PE - Perù 26
UZ - Uzbekistan 26
LT - Lituania 25
EG - Egitto 24
GR - Grecia 23
MY - Malesia 23
AU - Australia 22
CZ - Repubblica Ceca 22
CL - Cile 21
KE - Kenya 18
PT - Portogallo 18
PH - Filippine 17
AE - Emirati Arabi Uniti 16
UY - Uruguay 16
AL - Albania 15
IE - Irlanda 14
IL - Israele 14
KZ - Kazakistan 13
IR - Iran 12
NP - Nepal 12
RS - Serbia 12
TN - Tunisia 12
AZ - Azerbaigian 11
OM - Oman 11
BJ - Benin 10
CR - Costa Rica 10
TH - Thailandia 10
DK - Danimarca 9
DO - Repubblica Dominicana 9
ET - Etiopia 9
RO - Romania 9
DZ - Algeria 8
NZ - Nuova Zelanda 8
TT - Trinidad e Tobago 8
TW - Taiwan 8
BO - Bolivia 7
HN - Honduras 7
JM - Giamaica 7
JO - Giordania 7
BY - Bielorussia 6
EU - Europa 6
PA - Panama 6
BH - Bahrain 5
SV - El Salvador 5
BB - Barbados 4
GE - Georgia 4
HR - Croazia 4
PS - Palestinian Territory 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BS - Bahamas 3
CY - Cipro 3
GT - Guatemala 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
Totale 41.475
Città #
Ashburn 2.385
Hong Kong 2.202
Singapore 1.889
Fairfield 1.855
Woodbridge 1.840
Houston 1.317
Dallas 1.286
Ann Arbor 1.225
Santa Clara 1.185
Chandler 1.136
Shanghai 967
Seattle 798
Sofia 752
Cambridge 620
New York 614
Wilmington 594
Beijing 588
Milan 482
Boardman 464
Ottawa 320
Los Angeles 316
Princeton 316
Lawrence 301
Medford 258
Munich 235
Ho Chi Minh City 228
Hefei 211
Abidjan 193
Serra 190
Des Moines 188
Izmir 185
Boulder 174
London 170
Nanjing 164
Florence 159
São Paulo 151
Istanbul 149
Redondo Beach 147
Jacksonville 137
San Diego 125
Seoul 122
Dong Ket 119
Buffalo 117
Dearborn 116
Pisa 116
Hanoi 114
Turku 103
Frankfurt am Main 102
Dakar 89
Bremen 82
Ogden 75
Rome 75
Redwood City 72
Tokyo 71
Vienna 70
Nuremberg 69
Lancaster 62
Council Bluffs 61
Lagos 61
San Jose 60
Helsinki 57
Falls Church 56
Brussels 55
Nanchang 55
Rio de Janeiro 52
Belo Horizonte 48
Livorno 48
Pune 46
Kunming 42
Shenyang 42
Warsaw 42
Changsha 41
Columbus 41
The Dalles 41
Fuzhou 40
Norwalk 40
Curitiba 38
Porto Alegre 36
Bern 34
Chicago 34
Guangzhou 34
Hebei 34
Brasília 33
Brooklyn 30
San Francisco 30
Campinas 29
Denver 29
Düsseldorf 29
Montreal 29
Quito 28
Phoenix 27
Tianjin 27
Haiphong 26
Toronto 26
Jiaxing 25
Johannesburg 25
Poplar 25
Dhaka 24
Montecatini Terme 24
Salvador 24
Totale 29.718
Nome #
Treat-to-target in systemic lupus erythematosus: where are we today? 249
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force 236
Leukopenia, lymphopenia, andneutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review 223
Depression and systemic lupus erythematosus: a systematic review 221
Insomnia symptoms, perceived stress and coping strategies in patients with systemic lupus erythematosus 201
Impact of joint involvement on patients reported outcomes in systemic lupus erythematosus. 197
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 188
Gross Cystic Disease Fluid Protein-15(GCDFP-15)/Prolactin-Inducible Protein (PIP) as Functional Salivary Biomarker for Primary Sjögren's Syndrome 187
Impact of joint involvement on patients reported outcomes in systemic lupus erythematosus 183
null 179
Minor salivary gland biopsy and Sjögren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers. 175
TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review 172
Assessment of disease activity in systemic lupus erythematosus. 171
miRNA-mediated regulation of Mucin-type O-Glycosylation pathway: a putative mechanism of salivary gland dysfunction in Sjögren's syndrome 171
Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. 169
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein 167
Occurrence of hashimoto thyroiditis among the first- and second-degree relatives of systemic lupus erythematosus patients with Hashimoto thyroiditis 167
Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases 165
Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. 165
Mixed connective tissue disease. 164
Low FODMAP diet: Evidence, doubts, and hopes 163
Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. 162
Behçet's disease: features of neurological involvement in a dedicated centre in Italy. 161
In vivo confocal scanning laser microscopy in patients with primary Sjögren's syndrome: A monocentric experience. 160
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 160
Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literature 160
Undifferentiated connective tissue diseases (UCTD) 159
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity 159
Epidemiology and Management of Neuropsychiatric Disorders in Behçet's Syndrome. 158
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. 157
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 156
Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus 156
Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy 156
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. 156
The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus 156
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 156
Vascular reactivity in patients with undifferentiated connective tissue diseases 155
Changes of flow mediated dilation in pregnant patients with systemic autoimmune diseases 154
Treatment with Allogenic Mesenchymal Stromal Cells in a Murine Model of Systemic Lupus Erythematosus 154
Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 153
null 151
Platelet GPIIb/IIIa (P1A 1/2) polymorphism in SLE: clinical and laboratory association 150
Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases 149
The association of Sjögren syndrome and autoimmune thyroid disorders 149
Integrated backscatter analysis of carotid intima-media complex in patients with systemic lupus erythematosus 148
Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) 148
Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. 147
Poor sleep quality in systemic lupus erythematosus: does it depend on depressive symptoms 147
Prognostic value of flow mediated dilation in patients with systemic lupus erythematosus: A pilot prospective cohort study. 147
Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood. 147
Personalization of biologic therapy in patients with rheumatoid arthritis: Less frequently accounted choice-driving variables 146
Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews 145
Systemic lupus erythematosus one disease or many? 144
Bioelectrical impedance vector analysis in patients with irritable bowel syndrome on a low FODMAP diet: a pilot study 144
Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis 143
Undifferentiated connective tissue diseases (UCTD): Simplified systemic autoimmune diseases 142
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 142
null 141
Risk factors for osteoporosis in female patients with systemic lupus erythematosus 141
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study 140
The economic impact of gout: a systematic literature review. 139
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 139
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 138
The diagnosis and classification of undifferentiated connective tissue diseases. 137
Relapsing polychondritis: state of the art on clinical practice guidelines 137
Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology 136
Sjögren's syndrome: state of the art on clinical practice guidelines 136
Antiphospholipid syndrome: state of the art on clinical practice guidelines 136
Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres 135
Systemic sclerosis chronic ulcers: preliminary results of treatment with allogenic skin grafting in a cohort of Italian patients 134
[Long term outcome of treatment of diffuse proliferative glomerulonephritis with pulse steroids and short course pulse cyclophosphamide] 133
Outcome of pregnancy in Italian patients with primary Sjögren syndrome 133
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 133
Sexual dysfunction in Behçet's syndrome 133
A low-FODMAP diet for irritable bowel syndrome: Some answers to the doubts from a long-term follow-up 133
Alteration of microcirculation is a hallmark of very early systemic sclerosis patients: a laser speckle contrast analysis. 132
Systemic lupus erythematosus: state of the art on clinical practice guidelines 132
Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center 132
null 131
Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease 131
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. 131
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study 130
clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen 130
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 130
Post-occlusive reactive hyperaemia (POHR) in systemic sclerosis: very early disease (VEDOSS) represents a separate entity compared to established disease. 130
Phenotyping multiple subsets in Sjögren’s syndrome: a salivary proteomic SWATH-MS approach towards precision medicine 130
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus 130
The impact of skin calcinosis on digital ulcers in patients with SSc: clinical and prognostic stratification using the “wound bed score” 130
Emerging trends in Sjögren's syndrome: basic and translational research. 129
Prevalence of thyroid dysfunctions in systemic lupus erythematosus. 129
COVID-19: the new challenge for rheumatologists 129
Histopathology of the muscle in rheumatic diseases 128
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies 128
Framingham, ACC/AHA or QRISK3: which is the best in systemic lupus erythematosus cardiovascular risk estimation? 128
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice 127
Progressive sensorineural hearing impairment in systemic vasculitides 126
Aderenza allo screening per il cancro della cervice uterina in una coorte italiana di donne affette da LES [Adherence to cervical cancer screening in an Italian SLE cohort] 126
Pregnancy and undifferentiated connective tissue disease: outcome and risk of flare in 100 pregnancies 126
THU0264 MYELOID MALIGNANCIES, SYSTEMIC AUTOIMMUNE DISEASES AND CARDIOVASCULAR RISK: AN UNDER-REPORTED ASSOCIATION? 126
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) 125
Totale 15.070
Categoria #
all - tutte 127.545
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.545


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.513 0 0 0 0 0 0 434 218 249 147 134 331
2021/20223.303 105 154 66 214 608 538 107 161 134 153 208 855
2022/20233.703 523 495 234 325 418 455 54 258 635 23 247 36
2023/20243.117 221 264 302 169 429 598 302 120 66 39 219 388
2024/202511.202 65 409 248 603 864 1.181 1.216 582 1.127 1.523 1.267 2.117
2025/20268.466 856 1.603 1.795 1.681 1.421 1.082 28 0 0 0 0 0
Totale 42.391